Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 5,482,783 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Assembly Biosciences?
Among the largest hedge funds holding Assembly Biosciences’s share is Platinum Investment Management. It holds Assembly Biosciences’s shares valued at N/A.
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.
Copying Salim Syed's trades and holding each position for 1 Year would result in 7.69% of your transactions generating a profit, with an average return of -43.68% per trade.